Esperion Therapeutics Inc (NASDAQ:ESPR) Given Consensus Rating of “Buy” by Brokerages

Esperion Therapeutics Inc (NASDAQ:ESPR) has earned a consensus rating of “Buy” from the sixteen brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $72.69.

Several analysts recently commented on ESPR shares. BidaskClub lowered Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 5th. JPMorgan Chase & Co. lifted their price objective on Esperion Therapeutics from $46.00 to $47.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. Credit Suisse Group reaffirmed a “buy” rating and issued a $87.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, June 9th. Needham & Company LLC reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, May 7th. Finally, Bank of America started coverage on Esperion Therapeutics in a report on Wednesday, April 1st. They issued a “buy” rating and a $50.00 price objective for the company.

Shares of Esperion Therapeutics stock traded down $1.07 on Friday, reaching $45.90. The company’s stock had a trading volume of 764,823 shares, compared to its average volume of 684,292. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -4.77 and a beta of 2.16. The firm’s fifty day simple moving average is $44.50 and its two-hundred day simple moving average is $48.22. Esperion Therapeutics has a 52 week low of $24.82 and a 52 week high of $76.98. The company has a quick ratio of 2.33, a current ratio of 2.35 and a debt-to-equity ratio of 0.06.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.14) by $0.30. Esperion Therapeutics had a negative return on equity of 627.38% and a negative net margin of 5,492.02%. The business had revenue of $1.80 million during the quarter, compared to analyst estimates of $0.39 million. During the same quarter last year, the company earned $3.07 EPS. The company’s quarterly revenue was down 98.8% compared to the same quarter last year. As a group, research analysts predict that Esperion Therapeutics will post -4.95 EPS for the current year.

Several institutional investors have recently made changes to their positions in ESPR. Marshall Wace North America L.P. purchased a new stake in shares of Esperion Therapeutics in the fourth quarter valued at about $1,416,000. Brinker Capital Inc. acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $462,000. Janus Henderson Group PLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $234,000. Mutual of America Capital Management LLC purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $1,016,000. Finally, Amalgamated Bank purchased a new position in shares of Esperion Therapeutics during the fourth quarter valued at approximately $277,000.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: What is a Swap?

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.